Intellia Therapeutics, Inc. (NTLA) is a cutting-edge biotechnology company engaged in developing a revolutionary class of potential treatments aimed at addressing diseases with high unmet need. The company is focused on the development and commercialization of pioneering genome editing therapies using the CRISPR/Cas9 system.
Founded in 2014, Intellia is headquartered in Cambridge, Massachusetts, in the hub of the U.S. biotechnology industry. The company’s team consists of industry veterans, leading scientists, researchers, and professionals dedicated to transforming the lives of patients living with severe and life-threatening diseases.
At the core of their operations is the powerful gene-editing technology known as CRISPR/Cas9. This not only helps to modify disease-causing genes but also holds the potential of providing definitive, curative therapies to patients with genetic diseases. By harnessing the powerful capabilities of the CRISPR/Cas9 system, Intellia aims to develop treatments that can permanently eliminate diseases from a patient’s body, representing a quantum leap forward in the medical treatment of genetic diseases.
A key differentiator for Intellia lies in their strategic alliances with major pharmaceutical companies including Novartis and Regeneron. These partnerships help to accelerate the development and commercialization of their revolutionary gene-editing treatments.
The company's pipeline encompasses various programs for the treatment of rare genetic disorders such as transthyretin amyloidosis (ATTR) and hereditary angioedema, as well as several others including haemophilia A & B and sickle cell disease. Furthermore, Intellia also focuses on treating cancer through the development of cellular therapies.
Intellia is not only at the forefront of gene-editing therapies but is also on the cutting edge of the regulatory landscape. As a pioneer in the clinical application of CRISPR/Cas9, the company is working closely with regulatory authorities to both define and navigate this emerging field.
Proud of its progressive patient-centric approach, Intellia Therapeutics puts the patient at the forefront of everything they do. They align their goals with those of the patients they serve – to get safe, efficacious, and curative therapies to patients as quickly as possible. While its ambitions are grand, Intellia’s commitment is simple - to use its groundbreaking technology to make a real difference in people’s lives.
To date, Intellia Therapeutics, Inc., trading on the NASDAQ Stock Exchange with ticker NTLA, has established itself as a leader in the promising field of gene editing, moving one step closer to providing patients around the world with life-changing therapies.